Generalizability of the SURPASS‐2 Trial and Effect of Tirzepatide on US Diabetes and Obesity Control
Open Access
- 5 August 2022
- journal article
- letter
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 11 (16) , e026297
Abstract
No abstract availableKeywords
This publication has 3 references indexed in Scilit:
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 DiabetesNew England Journal of Medicine, 2021
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trialThe Lancet, 2021
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021Diabetes Care, 2020